UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
----------------------
FORM 10-Q
(X) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934.
FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 1998
OR
( ) TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934.
FOR THE TRANSITION PERIOD FROM ______ TO ______
Commission File Number 33-14582
PAINEWEBBER R&D PARTNERS II, L.P.
(Exact name of registrant as specified in its charter)
DELAWARE 13-3437420
(State or other jurisdiction of (I.R.S. Employer
Incorporation or organization) Identification No.)
1285 AVENUE OF THE AMERICAS, NEW YORK, NEW YORK 10019
(Address of principal executive offices) (Zip code)
Registrant's telephone number, including area code: (212) 713-2000
-----------------------
Indicate by check mark whether the Registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
Registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes [X] No [ ]
-----------------------
SPECIAL NOTE REGARDING
FORWARD LOOKING STATEMENTS
The Private Securities Litigation Reform Act of 1995 provides a "safe
harbor" for forward-looking statements. Except for the historical information
contained herein, the matters discussed herein are forward-looking statements.
Such forward-looking statements involve known and unknown risks, uncertainties
and other factors that may cause the actual results, performance or achievements
of PaineWebber R&D Partners II, L.P. or industry results to be materially
different from any future results, performance or achievements expressed or
implied by such forward-looking statements. Such factors include, among others,
the following: general economic and business conditions; fluctuations in the
value of securities for which only a limited, or no, public market exists;
dependence on the development of new technologies; dependence on timely
development and introduction of new and competitively priced products; the need
for regulatory approvals; the Sponsor Companies (hereinafter defined) having
insufficient funds to commercialize products to their maximum potential; the
restructuring of Sponsor Companies; the dependence of PaineWebber R&D Partners
II, L.P. on the skills of certain scientific personnel; and the dependence of
PaineWebber R&D Partners II, L.P. on the General Partner (hereinafter defined).
PAINEWEBBER R&D PARTNERS II, L.P.
(A DELAWARE LIMITED PARTNERSHIP)
FORM 10-Q
SEPTEMBER 30, 1998
Table of Contents
PART I. FINANCIAL INFORMATION Page
Item 1. Financial Statements
Statements of Financial Condition 2
(unaudited) at September 30, 1998
and December 31, 1997
Statements of Operations
(unaudited) for the three and nine
months ended September 30, 1998 and 3
1997
Statement of Changes in Partners'
Capital (unaudited) for the nine months
ended September 30, 1998 4
Statements of Cash Flows
(unaudited) for the nine months
ended September 30, 1998 and 1997 5
Notes to Financial Statements
(unaudited) 6-11
Item 2. Management's Discussion and 12-13
Analysis of Financial Condition and
Results of Operations
PART II. OTHER INFORMATION
Item 1. Legal Proceedings 14
Item 6. Exhibits and Reports on Form 8-K 14
Signatures 15
All schedules are omitted either because they are not applicable or the
information required to be submitted has been included in the financial
statements or notes thereto.
PART I FINANCIAL INFORMATION
Item 1. Financial Statements.
PAINEWEBBER R&D PARTNERS II, L.P.
(a Delaware Limited Partnership)
Statements of Financial Condition
(unaudited)
September 30, December 31,
1998 1997
- -------------------------------------------------------------------------------------------------------
Assets:
Cash $ 6,998 $ 6,998
Marketable securities, at market value 2,365,628 5,166,462
Royalty income receivable 1,461,326 1,105,048
Other asset - 5,000
================== =================
Total assets $ 3,833,952 $ 6,283,508
================== =================
Liabilities and partners' capital:
Accrued liabilities 63,361 78,770
Partners' capital 3,770,591 6,204,738
================== =================
Total liabilities and partners' capital $ 3,833,952 $ 6,283,508
================== =================
- -------------------------------------------------------------------------------------------------------
See notes to financial statements.
2
PAINEWEBBER R&D PARTNERS II, L.P.
(a Delaware Limited Partnership)
Statements of Operations
(unaudited)
For the three months ended September 30, 1998 1997
- -------------------------------------------------------------------------------------------------------
Revenues:
Interest income $ 3,758 $ 14,984
Income from product development projects 1,485,934 1,499,381
Unrealized (depreciation) appreciation of
investments and marketable securities (1,665,000) 683,701
------------------ -----------------
(175,308) 2,198,066
------------------ -----------------
Expenses:
General and administrative costs 42,731 125,335
------------------ -----------------
Net income (loss) $ (218,039) $ 2,072,731
================== =================
Net income (loss) per partnership unit:
Limited partners (based on 8,257 units) $ (26.14) $ 248.52
General partner $ (2,180.39) $ 20,727.31
- -------------------------------------------------------------------------------------------------------
For the nine months ended September 30, 1998 1997
- -------------------------------------------------------------------------------------------------------
Revenues:
Interest income $ 26,485 $ 71,305
Income from product development projects 5,151,173 6,552,481
Unrealized (depreciation) appreciation of
investments and marketable securities (3,930,000) 1,371,828
Realized gain (loss) on sale of investments
and marketable securities (1,939) 540,000
------------------ -----------------
1,245,719 8,535,614
------------------ -----------------
Expenses:
Expenditures under product development
projects - 20,483
General and administrative costs 135,195 222,608
------------------ -----------------
135,195 243,091
------------------ -----------------
Net income $ 1,110,524 $ 8,292,523
================== =================
Net income per partnership unit:
Limited partners (based on 8,257 units) $ 133.15 $ 994.26
General partner $ 11,105.24 $ 82,925.23
- -------------------------------------------------------------------------------------------------------
See notes to financial statements.
3
PAINEWEBBER R&D PARTNERS II, L.P.
(a Delaware Limited Partnership)
Statement of Changes in Partners' Capital
(unaudited)
Limited General
For the nine months ended September 30, 1998 Partners Partner Total
- ----------------------------------------------------------------------------------------------------------------------------
Balance at January 1, 1998 $ 6,138,610 $ 66,128 $ 6,204,738
Net income 1,099,419 11,105 1,110,524
Cash distributions (3,509,224) (35,447) (3,544,671)
------------------ ----------------- ----------------
Balance at September 30, 1998 $ 3,728,805 $ 41,786 $ 3,770,591
================== ================= ================
- ----------------------------------------------------------------------------------------------------------------------------
See notes to financial statements.
4
PAINEWEBBER R&D PARTNERS II, L.P.
(a Delaware Limited Partnership)
Statements of Cash Flows
(unaudited)
For the nine months ended September 30, 1998 1997
- -------------------------------------------------------------------------------------------------------
Cash flows from operating activities:
Net income $ 1,110,524 $ 8,292,523
Adjustments to reconcile net income to cash
provided by operating activities:
Unrealized depreciation (appreciation) of
investments and marketable securities 3,930,000 (1,371,828)
(Increase) decrease in operating assets:
Marketable securities (1,129,166) 753,466
Investments - (2,031,424)
Due from product development project - (886,544)
Advances to product development projects - 135,519
Royalty income receivable (356,278) 768,833
Other asset 5,000 -
(Decrease) increase in operating liabilities:
Due to product development project - (297,000)
Accrued liabilities (15,409) 59,688
------------------ -----------------
Cash provided by operating activities 3,544,671 5,423,233
------------------ -----------------
Cash flows from financing activities:
Distributions to partners (3,544,671) (5,421,262)
------------------ -----------------
Increase in cash - 1,971
Cash at beginning of period 6,998 5,028
------------------ -----------------
Cash at end of period $ 6,998 $ 6,999
================== =================
- -------------------------------------------------------------------------------------------------------
Supplemental disclosure of cash flow information:
The Partnership paid no cash for interest or taxes during the nine months ended September 30, 1998
and 1997.
- -------------------------------------------------------------------------------------------------------
See notes to financial statements.
5
PAINEWEBBER R&D PARTNERS II, L.P.
(A DELAWARE LIMITED PARTNERSHIP)
NOTES TO FINANCIAL STATEMENTS
(UNAUDITED)
1. ORGANIZATION AND BUSINESS
The financial information as of and for the periods ended September 30,
1998 and 1997 is unaudited. However, in the opinion of management of PaineWebber
R&D Partners II, L.P. (the "Partnership"), such information includes all
adjustments, consisting only of normal recurring accruals, necessary for a fair
presentation. The results of operations reported for the interim periods ended
September 30, 1998 are not necessarily indicative of results to be expected for
the year ended December 31, 1998. These financial statements should be read in
conjunction with the most recent annual report of the Partnership on Form 10-K
for the year ended December 31, 1997, and the previously issued quarterly
reports on Forms 10-Q for the quarters ended March 31 and June 30, 1998.
The Partnership is a Delaware limited partnership that commenced
operations on September 30, 1987 with a total of $72.0 million available for
investment. PWDC Holding Company (the "Manager") is the general partner of
PaineWebber Technologies II, L.P. (the "General Partner"), which is the general
partner of the Partnership. PWDC Holding Company is a wholly-owned subsidiary of
Paine Webber Development Corporation ("PWDC"), an indirect, wholly-owned
subsidiary of Paine Webber Group Inc. ("PWG"). The Partnership will terminate on
December 31, 2012, unless its term is extended or reduced by the General
Partner.
The principal objective of the Partnership has been to provide
long-term capital appreciation to investors through investing in the development
and commercialization of new products with technology companies ("Sponsor
Companies"), which have been expected to address significant market
opportunities. The Partnership has been engaged in diverse product development
projects (the "Projects") including product development contracts, participation
in other partnerships and investments in securities of the Sponsor Companies.
Once the product development phase has been completed, the Sponsor Companies
have had the option to license and commercialize the products resulting from the
product development project, and the Partnership has had the right to receive
payments based upon the sale of such products. The Partnership obtained warrants
to purchase the common stock of Sponsor Companies to provide additional capital
appreciation to the Partnership which was not directly dependent upon the
outcome of the Projects (see Note 5).
6
PAINEWEBBER R&D PARTNERS II, L.P.
(A DELAWARE LIMITED PARTNERSHIP)
NOTES TO FINANCIAL STATEMENTS
(UNAUDITED)
(NOTE 1 CONTINUED)
All distributions to the limited partners of the Partnership (the
"Limited Partners") and the General Partner (collectively, the "Partners") from
the Partnership have been made pro rata in accordance with their respective net
capital contributions. The following table sets forth the proportion of each
distribution to be received by the Limited Partners and the General Partner,
respectively:
LIMITED GENERAL
PARTNERS PARTNER
-------- -------
I. Until the value of the aggregate distributions for
each limited partnership unit ("Unit") equals
$10,000 plus simple interest on such amount
accrued at 7% per annum for each Unit sold at the
Initial Closing (6% per annum for each subsequent
Unit sold up to the 5,000th Unit and 5% per annum
for each Unit sold thereafter) ("Contribution
Payout"). At September 30, 1998, Contribution
Payout ranged from $14,625 per Unit to $17,700 per
Unit.............................................. 99% 1%
II. After Contribution Payout and until the value of
the aggregate distributions for each Unit equals
$50,000 ("Final Payout").......................... 80% 20%
III. After Final Payout................................ 75% 25%
The Partnership made no distributions during the quarter ended
September 30, 1998. The Partnership made cash distributions during the nine
months ended September 30, 1998 totaling $3,544,671 ($425 per Unit; $35,447 to
the General Partner). At September 30, 1998, the Partnership has made cash and
security distributions, as valued on the dates of distribution, since inception
of $3,001 and $7,206 per Unit, respectively.
Profits and losses of the Partnership are allocated as follows: (i)
until cumulative profits and losses for each Unit equals Contribution Payout,
99% to Limited Partners and 1% to the General Partner, (ii) after Contribution
Payout and until cumulative profits and losses for each Unit equals Final
Payout, 80% to Limited Partners and 20% to the General Partner, and (iii) after
Final Payout, 75% to Limited Partners and 25% to the General Partner. As of
September 30, 1998, the cumulative losses for the Partnership were $1,786 per
Unit.
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
The financial statements are prepared in conformity with generally
accepted accounting principles which require management to make certain
estimates and assumptions that affect the amounts reported in the financial
statements and accompanying notes. Actual results could differ from those
estimates.
Marketable securities consist of a money market fund and common stock
which are recorded at market value. Marketable securities are not considered
cash equivalents for the Statements of Cash Flows.
7
PAINEWEBBER R&D PARTNERS II, L.P.
(A DELAWARE LIMITED PARTNERSHIP)
NOTES TO FINANCIAL STATEMENTS
(UNAUDITED)
(NOTE 2 CONTINUED)
Realized and unrealized gains or losses are determined on a specific
identification method and are reflected in the Statements of Operations during
the period in which the change in value occurs.
The Partnership invests in product development contracts with Sponsor
Companies either directly or through product development limited partnerships.
The Partnership expenses product development costs when incurred by the Sponsor
Companies and such costs are reflected as expenditures under product development
projects in the accompanying Statements of Operations. Income received and/or
accrued from investments in Projects is reflected in the Statements of
Operations for the period in which the income is earned.
The Partnership carried warrants at a zero value in cases where the
Sponsor Company's stock was not publicly traded or the exercise period had not
been attained. To the extent the Partnership's warrants were currently
exercisable and the Sponsor Company's stock was publicly traded, the warrants
were carried at intrinsic value (the excess of market price per share over the
exercise price per share), which approximated fair value.
3. MARKETABLE SECURITIES AND INVESTMENTS
MARKETABLE SECURITIES:
The Partnership held the following marketable securities:
SEPTEMBER 30, 1998 DECEMBER 31, 1997
----------------------- ------------------------
MARKET COST MARKET COST
----------- ----------- ----------- -----------
Money market fund $ 1,525,626 $ 1,525,626 $ 98,335 $ 98,335
Cygnus, Inc. (255,000 common
shares) --- --- 5,068,127 2,524,500
(240,000 common
shares) 840,002 2,376,000 --- ---
----------- ----------- ----------- -----------
$ 2,365,628 $ 3,901,626 $ 5,166,462 $ 2,622,835
=========== =========== =========== ===========
In September 1997, the Partnership exercised its warrant for 255,000
shares of Cygnus, Inc. ("Cygnus") at an aggregate exercise price of $2,524,500
($9.90 per share). During the nine months ended September 30, 1998, the
Partnership sold 15,000 Cygnus shares (with a carrying value of $298,125) for
proceeds, net of commissions, of $296,186 ($19.75 per share). The market value
of Cygnus stock as of September 30, 1998, was $3.50 per share as compared to a
market value of $10.4375 and $19.875 per share as of June 30, 1998 and December
31, 1997, respectively. Accordingly, the Partnership recognized unrealized
depreciation on its Cygnus shares of $1,665,000 and $3,930,000 for the three
months and nine months ended September 30, 1998, respectively. The market value
of the Cygnus stock at September 30, 1997, was $19.75 per share as compared to a
carrying value of $17.25 and $14.50 per share at June 30, 1997 and December 31,
1996, respectively. The Partnership recognized unrealized appreciation of
$637,500 and $1,338,750 on its warrant to purchase 255,000 Cygnus shares for the
three and nine months ended September 30, 1997.
8
PAINEWEBBER R&D PARTNERS II, L.P.
(A DELAWARE LIMITED PARTNERSHIP)
NOTES TO FINANCIAL STATEMENTS
(UNAUDITED)
(NOTE 3 CONTINUED)
INVESTMENTS:
During the nine months ended September 30, 1997, the Partnership sold a
warrant to purchase 200,000 shares of OEC Medical Systems, Inc., ("OEC") with a
carrying value as of December 31, 1996 of $460,000, for proceeds of $1,000,000
and recognized a gain in the amount of $540,000 for the nine months ended
September 30, 1997.
4. RELATED PARTY TRANSACTIONS
The money market fund invested in by the Partnership is managed by an
affiliate of PaineWebber Incorporated ("PWI").
PWDC and PWI, and its affiliates, have acted in an investment banking
capacity for several of the Sponsor Companies. In addition, PWDC and its
affiliates have direct limited partnership interests in some of the same
Projects as the Partnership.
5. PRODUCT DEVELOPMENT PROJECTS
Of the Partnership's ten original Projects, three are ongoing or have
had current activity: Centocor Partners III, L.P. ("CP III"); Genzyme
Development Partners, L.P.; and Synergen Clinical Partners, L.P. ("SCP").
In February 1995, a Class A limited partner of SCP commenced an action
against the general partner of SCP and others. The complaint alleged that the
defendants caused or permitted the release of misleading statements regarding
the potential market for Interleukin-Receptor Antagonist ("IL-1ra") (a potential
treatment of inflammatory diseases), preclinical and clinical trial results, and
the possibility of IL-1ra becoming licensed for sale either in the United States
or Europe. The complaint sought damages on behalf of a class including limited
partners of SCP and limited partners of the Partnership (the "SCP Class"). On
December 2, 1997, the parties entered into a proposed settlement (the "SCP
Settlement") whereby the initial settlement payment to the SCP Class would
aggregate $16.5 million; class counsel would limit their request for attorney's
fees and costs to $3.0 million; and the SCP Class would be entitled to receive
rights to additional payments of $9.0 million (if the U.S. Food and Drug
Administration approves an IL-1ra product for market) and $50.0 million (if
IL-1ra product sales exceed $650 million before the year 2020). On January 16,
1998, the SCP Settlement received final approval from the court. On January 26,
1998, class counsel was awarded $3.0 million in fees and costs to be paid out of
the initial settlement payment. On March 3, 1998, the Partnership received and
recorded as income the amount of $1,248,624 representing its share of the
initial settlement payment as a Class A limited partner of SCP and,
simultaneously, SCP was terminated.
9
PAINEWEBBER R&D PARTNERS II, L.P.
(A DELAWARE LIMITED PARTNERSHIP)
NOTES TO FINANCIAL STATEMENTS
(UNAUDITED)
(NOTE 5 CONTINUED)
On January 31, 1997, pursuant to the provisions of the Partnership
Purchase Option Agreement between Centocor, Inc. ("Centocor") and the
Partnership, Centocor exercised its option to purchase the limited partnership
interests of CP III, including those owned by the Partnership. The Partnership
received an initial payment and is entitled to receive future quarterly payments
based on sales of ReoPro, a drug developed by CP III. For the nine months ended
September 30, 1998 and 1997, the Partnership received and/or accrued income from
CP III in the amount of $3,889,319 and $6,529,019 respectively.
If the Projects produce any product for commercial sale, the Sponsor
Companies have had the option to enter into joint ventures or royalty agreements
with the Partnership to manufacture and market the products developed. In
addition, the Sponsor Companies have had the option to purchase the
Partnership's interest in the technology. In consideration for such purchase
options, the Partnership received warrants to purchase shares of common stock of
the Sponsor Companies. As of September 30, 1998, the Partnership held no
warrants.
6. INCOME TAXES
The Partnership is not subject to federal, state or local income taxes.
Accordingly, the individual Partners are required to report their distributive
shares of realized income and loss on their individual federal and state income
tax returns.
7. LEGAL PROCEEDING
On July 12, 1995, the Partnership commenced a derivative action against
Centocor and Centocor Development Corporation III ("CDC III") in the Chancery
Court of Delaware (the "Court") arising from certain agreements entered into by
Centocor and Eli Lilly & Company ("Lilly") in July 1992. The Partnership's
complaint alleges, among other things that: at least $25 million of the $100
million paid by Lilly to Centocor represents profits from the sale of ReoPro, a
Centocor drug, that Centocor is required to share with CP III; and because of
the Lilly transaction, Centocor was required to increase the percentages of
profits and revenues from ReoPro that it pays to CP III investors. Centocor had
taken the position that only $500,000 of the $100 million had to be shared with
CP III and that Centocor had no obligation to increase the percentages of ReoPro
profits and revenues that it pays to CP III investors. The Partnership sought to
proceed on behalf of CP III. The complaint seeks to require Centocor and CDC III
to pay damages to CP III and to increase the percentages of future ReoPro
profits and revenues that Centocor must pay to CP III and its investors.
Centocor answered the Partnership's complaint, as well as a similar
complaint filed by John E. Abdo, another limited partner of CP III, denying the
material allegations of those complaints and asserting purported affirmative
defenses and third-party claims against PWG, PWDC and PWI.
In April and July 1996, Mr. Abdo moved to amend his complaint to assert
claims on behalf of CP III against two of PWDC's nominees to the CDC III Board
of Directors. On July 12, 1996, counsel chosen by Centocor to represent CP III
moved to disqualify the Partnership from serving as a plaintiff in this action,
alleging that Mr. Abdo should be the sole plaintiff because the Partnership has
conflicts of interest with CP III and its other limited partners, including
conflicts arising out of the alleged claims against the PWDC nominees. Mr. Abdo
and Centocor also moved to disqualify the Partnership. In January 1997, the
Court
10
PAINEWEBBER R&D PARTNERS II, L.P.
(A DELAWARE LIMITED PARTNERSHIP)
NOTES TO FINANCIAL STATEMENTS
(UNAUDITED)
(NOTE 7 CONTINUED)
granted, in part, Mr. Abdo's motion to amend his complaint to assert claims
against the PWDC nominees. The Court has not ruled on the motions to disqualify.
In June 1997, the parties to the Partnership's action entered into an agreement
to settle the action. The agreement provides, among other things, for Centocor
to pay to CP III investors (including the Partnership, a former limited partner
in CP III) in the aggregate: $10.8 million, net of attorneys' fees and expenses
as may be awarded by the Court; an additional $5.0 million, if and when
cumulative world-wide sales of ReoPro exceed $600 million; and possible
additional payments totaling $2.2 million, depending upon regulatory
developments in Japan. The Partnership will only receive its allocable share of
these amounts if, and when, payments under the agreement are remitted by
Centocor.
The agreement further provides for revisions to the ReoPro royalties
payable by Centocor to CP III investors through 2007. Under the agreement, those
royalties would be paid based on revenues from end-sales by Lilly and other
distributors, as opposed to Centocor's revenues on its sales to distributors.
For 1997 and 1998, Centocor would pay an aggregate of 6.5% of the first $175
million of United States end-sale revenues, 3.25% of such revenues above $175
million, and 3.25% of foreign end-sales revenues. For 1999 through 2007,
Centocor would pay an aggregate of 6.5% of the first $250 million of United
States end-sale revenues, 4% of such revenues above $250 million, and 3.25% of
foreign end-sales revenues. The agreement provides that investors will not
receive less than Centocor would otherwise have paid based on Centocor's sales
of ReoPro. As of September 30, 1998, the Partnership has not accrued income
related to the settlement.
On June 27, 1997, the Court entered an order: preliminarily approving
the settlement; providing for notice to a class consisting of all holders of CP
III Class A and C limited partnership interests as of the close of business on
January 31, 1997, and all holders of CP III Class B limited partnership
interests as of the close of business on May 31, 1997, and their transferees,
successors, and assigns, other than defendants; and designating the
Partnership's counsel as counsel for the class.
Mr. Abdo and Pharmaceutical Partners, L.P., another former limited
partner of CP III, have objected to the proposed settlement. They have asserted,
among other things, that the consideration is inadequate and that the proposed
allocations of the consideration among the classes of former limited partners of
CP III improperly favors the Partnership. On September 4, 1997, the Court held a
hearing on the objections and reserved decision.
PWDC has been advancing, and may continue to advance, the funds
necessary to pay the Partnership's legal fees and expenses relating to this
litigation. In the event of a recovery on behalf of CP III, the Court may award
legal fees and expenses to the Partnership's counsel to be paid out of the CP
III recovery. Counsel for the Partnership has stated that they intend to apply
to the Court for an award of fees and expenses in an amount up to $1.5 million.
Counsel for Mr. Abdo has stated that he intends to object to any such
application, and, if the settlement is approved, will himself apply for an award
of fees and expenses. It is anticipated that: the net proceeds of any recovery
will be distributed to the limited partners of CP III, including the
Partnership, on a pro rata basis; the Partnership and/or its counsel will
reimburse PWDC; and any remaining Partnership proceeds will be distributed to
the Partners of the Partnership in accordance with the distribution criteria
outlined in Note 1.
11
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS.
LIQUIDITY AND CAPITAL RESOURCES
Partners' capital decreased from $6.2 million at December 31, 1997, to
$3.8 million at September 30, 1998 resulting from the recognition of income of
$1.1 million for the nine months ended September 30, 1998 (as more fully
explained in Results of Operations below) offset by a cash distribution to
Partners of $3.5 million.
The Partnership's working capital is invested in marketable securities
including a money market fund. Liquid assets at September 30, 1998 and December
31, 1997 were $2.4 and $5.2 million, respectively. The decrease of $2.8 million
was due primarily to a decline from December 31, 1997 to September 30, 1998 in
the market value of securities held by the Partnership of $3.9 million offset by
proceeds received from a Project of $1.2 million. The balance of liquid assets
will be used for the payment of administrative costs related to managing the
Partnership's business and future distributions to the Partners.
RESULTS OF OPERATIONS
THREE MONTHS ENDED SEPTEMBER 30, 1998 COMPARED TO THE THREE MONTHS ENDED
SEPTEMBER 30, 1997:
Net income (loss) for the quarters ended September 30, 1998 and 1997
was $(0.2) million and $2.1 million, respectively. The unfavorable variance of
$2.3 million resulted primarily from a decrease in revenues.
Revenues for the quarters ended September 30, 1998 and 1997 were $(0.2)
million and $2.2 million, respectively. The decrease was due to an unfavorable
change in unrealized appreciation (depreciation) of investments and marketable
securities relating to the Partnership's investment in shares of Cygnus stock.
Unrealized appreciation (depreciation) of investments and marketable securities
for the quarters ended September 30, 1998 and 1997 was $(1.7) million and $0.7
million, respectively. The market value of Cygnus shares decreased from $10.4375
per share at June 30, 1998 to $3.50 per share at September 30, 1998 resulting in
the recognition of unrealized depreciation of $1.7 million for the three months
ended September 30, 1998 on the Partnership's investment of 0.24 million shares.
For the three months ended September 30, 1997, the Partnership recognized
unrealized appreciation of $0.7 million with respect to its warrant to purchase
0.255 million common shares of Cygnus. The market value of the shares increased
from $17.25 per share as of June 30, 1997 to $19.75 per share at September 30,
1997.
There were no material variances in expenses for the quarter ended
September 30, 1998 as compared to the same period in 1997.
NINE MONTHS ENDED SEPTEMBER 30, 1998 COMPARED TO THE NINE MONTHS ENDED
SEPTEMBER 30, 1997:
Net income for the nine months ended September 30, 1998 and 1997 was
$1.1 million and $8.3 million, respectively. The unfavorable variance of $7.2
million resulted primarily from a decrease in revenues.
12
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS.
Revenues for the nine months ended September 30, 1998 and 1997 were
$1.3 million and $8.5 million, respectively. The decrease of $7.2 million was
due primarily to decreases of $1.4 million in income from product development
projects; $0.5 million in gain on the sale of investments and marketable
securities; and an unfavorable change in unrealized appreciation (depreciation)
of investments and marketable securities of $5.3 million. For the nine months
ended September 30, 1997, the Partnership sold its warrant to purchase 0.2
million shares of OEC with a carrying value equal to its intrinsic value as of
December 31, 1996 of $0.5 million for proceeds of $1.0 million and recognized a
gain of $0.5 million from the sale. Income from product development projects for
the nine months ended September 30, 1998 and 1997 was $5.2 million and $6.6
million, respectively. On January 31, 1997, Centocor exercised its option to
purchase the limited partnership interests of CP III (including those owned by
the Partnership) for an initial payment and the right to receive quarterly
future payments based upon sales of certain products developed by CP III. The
Partnership received and/or accrued income due from CP III of $6.6 million for
the nine months ended September 30, 1997. For the nine months ended September
30, 1998, the Partnership received and/or accrued income due in connection with
its former investment in CP III of $3.9 million. Also during this period, the
Partnership recognized income from its former investment in SCP in the amount of
$1.2 million representing its share of the initial settlement payment received
as a Class A limited partner of SCP. Unrealized appreciation (depreciation) of
investments and marketable securities for the nine months ended September 30,
1998 and 1997 was $(3.9) million and $1.4 million, respectively. The market
value of the Partnership's investment in 0.24 million shares of Cygnus decreased
from $19.875 per share as of December 31, 1997 to $3.50 per share at September
30, 1998. The market value of the Cygnus shares increased from $14.50 per share
as of December 31,1996 to $19.75 per share at September 30, 1997, resulting in
the recognition of unrealized appreciation of $1.4 million on the Partnership's
warrant to purchase 0.255 Cygnus shares.
There were no material variances in expenses for the nine months ended
September 30, 1998 as compared to the same period in 1997.
YEAR 2000
The Year 2000 Issue is the result of computer programs being written
using two digits rather than four to define the applicable year. Calculations
performed with these abbreviated date fields may misinterpret the Year 2000 as
1900 resulting in erroneous calculations or program failures. Currently, the
Partnership utilizes computer programs, through services provided by a
third-party servicing agent, that can adversely affect the Partnership's
operations if they are not Year 2000 compliant. The servicing agent has informed
the Partnership that it is executing a plan to modify or replace significant
applications as necessary to ensure Year 2000 compliance. Programming changes
and initial testing are in progress and expected to be completed by year-end.
Final testing is expected to be completed by May 1999. Conversion of client
databases will commence in May 1999. The servicing agent has not quantified the
extent to which their plan has been completed to date. Incremental costs
associated with the development and implementation of the above plan have been,
and will continue to be, borne by the servicing agent. The status of the
Partnership's investments in Sponsor Companies could be adversely affected if
the computer systems of the Sponsor Companies are not Year 2000 compliant. Based
on the most recent available public disclosures of those Sponsor Companies in
which the Partnership has investments of value, the Sponsor Companies have
stated that they have undertaken programs to insure Year 2000 compliance. As of
the dates of disclosure, these Sponsor Companies have stated that they do not
expect that the Year 2000 Issue will adversely effect their future financial
condition. However, they cannot provide assurances that unanticipated problems
and costs will not arise. To date, the Partnership has no contingency plan in
place but intends to evaluate the status of the Year 2000 Issue with third
parties in March 1999 to determine whether such a plan is necessary.
13
PART II OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS.
ACTION AGAINST CENTOCOR, INC. AND CENTOCOR DEVELOPMENT CORPORATION III.
Information regarding this action was disclosed on the
Partnership's Form 10-K for the year ended December 31, 1997.
ACTION AGAINST AMGEN BOULDER, INC.
Information regarding this action was disclosed on the
Partnership's Form 10-K for the year ended December 31, 1997 and the
Partnership's Form 10-Q for the quarter ended March 31, 1998.
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K.
A) EXHIBITS:
None
B) REPORTS ON FORM 8-K:
None
14
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized, on this 16th day of
November 1998.
PAINEWEBBER R&D PARTNERS II, L.P.
By: PaineWebber Technologies II, L.P.
(General Partner)
By: PWDC Holding Company
(general partner of the General Partner)
By: /s/ Dhananjay M.Pai
-------------------
Dhananjay M.Pai
President*
By: /s/ Anthony M. DiIorio
----------------------
Anthony M. DiIorio
Principal Financial and Accounting Officer*
* The capacities listed are with respect to PWDC Holding Company, the Manager,
as well as PWDC, the parent company of the Manager.
15